Lopicic Milena, Raonic Janja, Antunovic Marija, Milicic Biljana, Mijovic Gordana
1Institute of Public Health of Montenegro, Podgorica, Montenegro.
2Clinical Centre of Montenegro, Podgorica, Montenegro.
Acta Microbiol Immunol Hung. 2021 Nov 1. doi: 10.1556/030.2021.01606.
Cervical cancer (CC) is the third leading cause of death in women in Montenegro. Human papillomavirus (HPV) is the causative agent of CC however, HPV genotype distribution varies across regions. This study examined the distribution and impact of vaccine-related high-risk (HR)-HPVs on the development of cervical dysplasia in Montenegrin women. A total of 187 women who had a clinical indication for cervical biopsy were enrolled. Based on histopathological findings, women were classified into 2 groups, with and without dysplasia. HR-HPV was detected by real-time PCR. Twelve HR-HPV genotypes were detected in 40.6% of cervical samples. The 7 most prevalent HR-HPVs in order of decreasing frequency were HPV 16 (39.5%), 45 (23.7%), 31 (21.0%), 33 (17.1%), 18 (6.6%), 52 (6.6%), and 58 (6.6%), all of them are targeted by nonavalent vaccine. Vaccine-related HR-HPVs had a higher prevalence (92.1%) than the other HR-HPVs detected in HR-HPV-positive samples. Among HR-HPV-positive women, HPV 16 and 33 were more common in women with dysplasia than in those without dysplasia (HPV 16: 28.9 vs 7.2%; HPV 33: 11.8 vs 3.6%). HPV 16 was the most common HR-HPV genotype in cervical samples, followed by HPV 45, 31, 33, 18, 52, and 58. HPV 16 and 33 were shown to be associated with the development of cervical dysplasia. These results indicate that prophylactic nonavalent vaccine can potentially prevent approximately 90% of HR-HPV infections and 60% of cervical dysplasia cases in Montenegrin women.
宫颈癌（CC）是黑山共和国女性的第三大死因。人乳头瘤病毒（HPV）是宫颈癌的致病因子，然而，HPV基因型分布因地区而异。本研究调查了与疫苗相关的高危（HR）-HPV在黑山共和国女性宫颈发育异常发生中的分布及影响。共有187名有宫颈活检临床指征的女性入组。根据组织病理学结果，将女性分为两组，有发育异常组和无发育异常组。通过实时聚合酶链反应检测HR-HPV。在40.6%的宫颈样本中检测到12种HR-HPV基因型。按频率递减顺序排列的7种最常见的HR-HPV分别是HPV 16（39.5%）、45（23.7%）、31（21.0%）、33（17.1%）、18（6.6%）、52（6.6%）和58（6.6%），这些均为九价疫苗的目标型别。在HR-HPV阳性样本中，与疫苗相关的HR-HPV的流行率（92.1%）高于其他检测到的HR-HPV。在HR-HPV阳性女性中，HPV 16和33在有发育异常的女性中比在无发育异常的女性中更常见（HPV 16：28.9%对7.2%；HPV 33：11.8%对3.6%）。HPV 16是宫颈样本中最常见的HR-HPV基因型，其次是HPV 45、31、33、18、52和58。研究表明，HPV 16和33与宫颈发育异常的发生有关。这些结果表明，预防性九价疫苗有可能预防黑山共和国女性中约90%的HR-HPV感染和60%的宫颈发育异常病例。
